Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Starting soon · Phase 4

Conditions studied: Duchenne Muscular Dystrophy

In brief

The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.

Key facts

Study ID

NCT07542314

Run by

Sarepta Therapeutics, Inc.

People needed

20

Starts

2026-07-31

Expected to finish

2027-03-31

Last updated by the study team

2026-05-26

Who can join

Age: 4 and older. Sex: male. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.